Company · CIK 0000875045 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
BIOGEN INC. · BIIB
Insider activity reported against this company. All insider holders · Files at: BIVV. On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2017 PForm 4 → | Mar 1, 4:18 pm EST | Michel VounatsosChief Executive Officer, Director | 1,333 | $285.39 | $380,425 | 1,434 | +1,321% | plan? |
| Jan 9, 2017 SForm 4 → | Jan 10, 4:15 pm EST | Robert W PangiaDirector | 5,450 | $295.39 | $1,609,876 | 16,628 | −24.7% | plan? |
| Jan 9, 2017 MForm 4 → | Jan 10, 4:15 pm EST | Robert W PangiaDirector | 5,450 | $52.22 | $284,599 | 22,078 | — | plan? |
| Dec 1, 2016 SForm 4 → | Dec 5, 4:34 pm EST | Adriana KaraboutisEVP, Tech, Bus. Sol & Corp Aff | 48 | $296.53 | $14,233 | 7,360 | −0.65% | plan? |
| Dec 1, 2016 FForm 4 → | Dec 5, 4:34 pm EST | Adriana KaraboutisEVP, Tech, Bus. Sol & Corp Aff | 171 | $295.78 | $50,578 | 7,408 | — | plan? |
| Dec 1, 2016 AFForm 4 → | Dec 5, 4:32 pm EST | Gregory F CovinoVP, Chief Accounting Officer | 983 | $295.78 | $15,676 | 3,884 | — | plan? |
| Nov 8, 2016 GForm 4 → | Nov 14, 4:32 pm EST | Stephen A SherwinDirector | 1,000 | — | — | 4,905 | — | plan? late |
| Oct 4, 2016 SForm 4 → | Oct 5, 4:24 pm EDT | Adriana KaraboutisEVP, Tech, Bus. Sol & Corp Aff | 262 | $311.94 | $81,728 | 7,579 | −3.34% | plan? |
| Oct 3, 2016 SForm 4 → | Oct 4, 5:02 pm EDT | Adriana KaraboutisEVP, Tech, Bus. Sol & Corp Aff | 380 | $313.00 | $118,940 | 7,841 | −4.62% | plan? |
| Oct 1, 2016 FMForm 4 → | Oct 4, 5:02 pm EDT | Adriana KaraboutisEVP, Tech, Bus. Sol & Corp Aff | 3,870 | $313.03 | $591,001 | 8,221 | — | plan? |
| Sep 22, 2016 SForm 4 → | Sep 26, 4:24 pm EDT | Caroline DorsaDirector | 27,570 | $314.00 | $8,656,980 | 17,093 | −61.7% | plan? |
| Sep 22, 2016 MForm 4 → | Sep 26, 4:24 pm EDT | Caroline DorsaDirector | 27,570 | $53.64 | $1,478,855 | 44,663 | — | plan? |
| Jul 21, 2016 SForm 4 → | Jul 22, 5:03 pm EDT | George A ScangosChief Executive Officer, Director | 157 | $280.00 | $43,960 | 54,779 | −0.29% | plan? |
| Jun 8, 2016 AForm 4 → | Jun 9, 5:23 pm EDT | Alexander J DennerDirector | 1,060 | — | — | 8,950 | — | plan? |
| Jun 8, 2016 AForm 4 → | Jun 9, 4:46 pm EDT | Stephen A SherwinDirector | 1,060 | — | — | 5,905 | — | plan? |
| Jun 8, 2016 AForm 4 → | Jun 9, 4:45 pm EDT | Lynn SchenkDirector | 1,060 | — | — | 5,950 | — | plan? |
| Jun 8, 2016 AForm 4 → | Jun 9, 4:44 pm EDT | Eric K RowinskyDirector | 1,060 | — | — | 13,065 | — | plan? |
| Jun 8, 2016 AForm 4 → | Jun 9, 4:43 pm EDT | Stelios PapadopoulosDirector | 1,590 | — | — | 18,170 | — | plan? |
| Jun 8, 2016 AForm 4 → | Jun 9, 4:41 pm EDT | Richard MulliganDirector | 1,060 | — | — | 8,950 | — | plan? |
| Jun 8, 2016 AForm 4 → | Jun 9, 4:39 pm EDT | Nancy LeamingDirector | 1,060 | — | — | 8,984 | — | plan? |
| Jun 8, 2016 AForm 4 → | Jun 9, 4:38 pm EDT | Caroline DorsaDirector | 1,060 | — | — | 17,093 | — | plan? |
| Jun 8, 2016 AForm 4 → | Jun 9, 4:37 pm EDT | Robert W PangiaDirector | 1,060 | — | — | 16,628 | — | plan? |
| Jun 8, 2016 AForm 4 → | Jun 9, 4:33 pm EDT | Brian S PosnerDirector | 1,060 | — | — | 6,335 | — | plan? |
| Jun 6, 2016 SForm 4 → | Jun 7, 4:09 pm EDT | Adam KoppelEVP, Strategy and Bus. Dev. | 555 | $290.00 | $160,950 | 2,402 | −18.8% | plan? |
| Jun 3, 2016 SForm 4 → | Jun 6, 8:14 pm EDT | George A ScangosChief Executive Officer, Director | 842 | $290.00 | $244,180 | 54,936 | −1.51% | plan? |
| Jun 2, 2016 FMForm 4 → | Jun 6, 8:48 pm EDT | Adam KoppelEVP, Strategy and Bus. Dev. | 2,177 | $289.73 | $154,716 | 2,957 | — | plan? |
| Jun 1, 2016 AForm 4 → | Jun 2, 4:44 pm EDT | Michael D EhlersEVP, Research and Development | 3,034 | — | — | 3,034 | — | plan? |
| May 31, 2016 SForm 4 → | Jun 2, 4:39 pm EDT | George A ScangosChief Executive Officer, Director | 3,855 | $289.74 | $1,116,961 | 55,778 | −6.46% | plan? |
| May 25, 2016 SForm 4 → | May 27, 8:59 am EDT | George A ScangosChief Executive Officer, Director | 157 | $280.00 | $43,960 | 59,633 | −0.26% | plan? |
| May 2, 2016 SForm 4 → | May 4, 5:03 pm EDT | George A ScangosChief Executive Officer, Director | 487 | $274.74 | $133,798 | 59,790 | −0.81% | plan? |
| May 1, 2016 FMForm 4 → | May 2, 4:36 pm EDT | Gregory F CovinoVP, Chief Accounting Officer | 461 | $274.99 | $31,074 | 3,007 | — | plan? |
| Apr 6, 2016 SForm 4 → | Apr 7, 5:03 pm EDT | Adam KoppelEVP, Strategy and Bus. Dev. | 102 | $275.00 | $28,050 | 1,848 | −5.23% | plan? |
| Apr 6, 2016 SForm 4 → | Apr 7, 5:01 pm EDT | George A ScangosChief Executive Officer, Director | 157 | $280.00 | $43,960 | 60,277 | −0.26% | plan? |
| Apr 2, 2016 FMForm 4 → | Apr 5, 5:06 pm EDT | Spyridon Artavanis-TsakonasEVP, Chief Scientific Officer | 1,434 | $260.54 | $119,588 | 3,150 | — | plan? |
| Apr 1, 2016 AForm 4 → | Apr 5, 5:04 pm EDT | John CoxEVP Pharmaceutical Oper & Tech | 8,444 | — | — | 39,045 | — | plan? |
| Apr 1, 2016 SForm 4 → | Apr 5, 5:02 pm EDT | George A ScangosChief Executive Officer, Director | 487 | $258.83 | $126,050 | 60,434 | −0.80% | plan? |
| Mar 1, 2016 SForm 4 → | Mar 3, 4:36 pm EST | George A ScangosChief Executive Officer, Director | 487 | $261.37 | $127,287 | 60,921 | −0.79% | plan? |
| Feb 25, 2016 SForm 4 → | Feb 26, 4:08 pm EST | Alfred SandrockEVP CMO Neuro & Neurodegenerat | 183 | $261.90 | $47,928 | 7,990 | −2.24% | plan? |
| Feb 25, 2016 SForm 4 → | Feb 26, 4:06 pm EST | Adriana KaraboutisEVP, Tech, Bus. Sol & Corp Aff | 84 | $261.90 | $22,000 | 8,127 | −1.02% | plan? |
| Feb 23, 2016 FMForm 4 → | Feb 25, 5:13 pm EST | Paul J ClancyExecutive VP and CFO | 852 | $258.99 | $70,704 | 26,870 | — | plan? |
| Feb 23, 2016 FMForm 4 → | Feb 25, 5:09 pm EST | Gregory F CovinoVP, Chief Accounting Officer | 88 | $258.99 | $5,698 | 2,687 | — | plan? |
| Feb 23, 2016 FMForm 4 → | Feb 25, 5:07 pm EST | Spyridon Artavanis-TsakonasSVP, Chief Scientific Officer | 193 | $258.99 | $12,432 | 2,549 | — | plan? |
| Feb 23, 2016 FMForm 4 → | Feb 25, 5:05 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 936 | $258.99 | $77,697 | 31,840 | — | plan? |
| Feb 23, 2016 FMForm 4 → | Feb 25, 5:04 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 1,192 | $258.99 | $98,934 | 30,516 | — | plan? |
| Feb 23, 2016 FMForm 4 → | Feb 25, 5:02 pm EST | Adam KoppelEVP, Strategy and Bus. Dev. | 399 | $258.99 | $25,381 | 1,865 | — | plan? |
| Feb 23, 2016 FMForm 4 → | Feb 25, 5:01 pm EST | Kenneth DiPietroEVP Human Resources | 936 | $258.99 | $77,697 | 3,937 | — | plan? |
| Feb 23, 2016 FMForm 4 → | Feb 25, 4:59 pm EST | Steven H HoltzmanEVP Corporate Development | 852 | $258.99 | $70,704 | 8,326 | — | plan? |
| Feb 23, 2016 FMForm 4 → | Feb 25, 4:57 pm EST | Adriana KaraboutisEVP, Tech, Bus. Sol & Corp Aff | 660 | $258.99 | $41,956 | 8,211 | — | plan? |
| Feb 23, 2016 FMForm 4 → | Feb 25, 4:52 pm EST | Alfred SandrockEVP CMO Neuro & Neurodegenerat | 511 | $258.99 | $42,474 | 8,173 | — | plan? |
| Feb 23, 2016 FMForm 4 → | Feb 25, 4:51 pm EST | George A ScangosChief Executive Officer, Director | 4,359 | $258.99 | $361,291 | 61,417 | — | plan? |
| Feb 17, 2016 SForm 4 → | Feb 19, 4:20 pm EST | George A ScangosChief Executive Officer, Director | 487 | $256.16 | $124,750 | 59,848 | −0.81% | plan? |
| Feb 17, 2016 SForm 4 → | Feb 19, 4:18 pm EST | Alfred SandrockEVP CMO Neuro & Neurodegenerat | 722 | $256.16 | $184,948 | 7,990 | −8.29% | plan? |
| Feb 12, 2016 AFMForm 4 → | Feb 17, 6:03 pm EST | George A ScangosChief Executive Officer, Director | 36,906 | $247.22 | $2,920,904 | 60,335 | — | plan? |
| Feb 12, 2016 FMForm 4 → | Feb 17, 6:01 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 4,850 | $247.22 | $383,685 | 30,088 | — | plan? |
| Feb 12, 2016 FMForm 4 → | Feb 17, 6:00 pm EST | Kenneth DiPietroEVP Human Resources | 4,685 | $247.22 | $338,444 | 3,601 | — | plan? |
| Feb 12, 2016 FMForm 4 → | Feb 17, 5:59 pm EST | Gregory F CovinoVP, Chief Accounting Officer | 451 | $247.22 | $6,428 | 2,643 | — | plan? |
| Feb 12, 2016 FMForm 4 → | Feb 17, 5:57 pm EST | Alfred SandrockEVP CMO Neuro & Neurodegenerat | 4,626 | $247.22 | $451,671 | 8,712 | — | plan? |
| Feb 12, 2016 FMForm 4 → | Feb 17, 5:56 pm EST | Steven H HoltzmanEVP Corporate Development | 4,508 | $247.22 | $324,847 | 8,020 | — | plan? |
| Feb 12, 2016 FMForm 4 → | Feb 17, 5:55 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 4,617 | $247.22 | $328,308 | 31,504 | — | plan? |
| Feb 12, 2016 FMForm 4 → | Feb 17, 5:54 pm EST | Spyridon Artavanis-TsakonasSVP, Chief Scientific Officer | 1,409 | $247.22 | $87,021 | 2,452 | — | plan? |
| Feb 12, 2016 FMForm 4 → | Feb 17, 5:53 pm EST | Paul J ClancyExecutive VP and CFO | 5,558 | $247.22 | $420,027 | 26,564 | — | plan? |
| Feb 9, 2016 FMForm 4 → | Feb 10, 4:19 pm EST | George A ScangosChief Executive Officer, Director | 16,579 | $249.99 | $1,326,197 | 47,059 | — | plan? |
| Feb 9, 2016 SForm 4 → | Feb 10, 4:17 pm EST | Alfred SandrockEVP CMO Neuro & Neurodegenerat | 852 | $246.54 | $210,052 | 7,740 | −9.92% | plan? |
| Feb 8, 2016 FMForm 4 → | Feb 10, 4:17 pm EST | Alfred SandrockEVP CMO Neuro & Neurodegenerat | 1,704 | $250.77 | $106,828 | 8,592 | — | plan? |
| Feb 8, 2016 FMForm 4 → | Feb 9, 4:58 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 3,320 | $250.77 | $206,133 | 29,543 | — | plan? |
| Feb 8, 2016 FMForm 4 → | Feb 9, 4:53 pm EST | Paul J ClancyExecutive VP and CFO | 4,241 | $250.77 | $262,556 | 24,404 | — | plan? |
| Feb 8, 2016 FMForm 4 → | Feb 9, 4:51 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 5,350 | $250.77 | $332,019 | 28,342 | — | plan? |
| Feb 8, 2016 FMForm 4 → | Feb 9, 4:48 pm EST | Steven H HoltzmanEVP Corporate Development | 3,599 | $250.77 | $223,185 | 6,140 | — | plan? |
| Feb 1, 2016 MForm 4/A → | Feb 9, 5:08 pm EST | Kenneth DiPietroEVP Human Resources | 2,466 | — | — | 2,466 | — | plan? |
| Feb 1, 2016 FMForm 4 → | Feb 2, 4:05 pm EST | Kenneth DiPietroEVP Human Resources | 3,278 | $273.45 | $896,369 | 1,654 | — | plan? amended |
| Dec 4, 2015 SForm 4 → | Dec 7, 4:20 pm EST | Alfred SandrockEVP CMO Neuro & Neurodegenerat | 441 | $277.00 | $122,157 | 7,740 | −5.39% | plan? |
| Dec 3, 2015 FForm 4 → | Dec 7, 4:20 pm EST | Alfred SandrockEVP CMO Neuro & Neurodegenerat | 393 | $275.44 | $108,248 | 8,181 | — | plan? |
| Dec 2, 2015 SForm 4 → | Dec 3, 4:19 pm EST | Adriana KaraboutisEVP, Tech. and Bus. Solutions | 48 | $289.14 | $13,879 | 7,875 | −0.61% | plan? |
| Dec 1, 2015 FForm 4 → | Dec 3, 4:19 pm EST | Adriana KaraboutisEVP, Tech. and Bus. Solutions | 171 | $290.04 | $49,597 | 7,923 | — | plan? |
| Dec 1, 2015 AForm 4 → | Dec 3, 4:17 pm EST | Gregory F CovinoVP, Chief Accounting Officer | 483 | — | — | 2,244 | — | plan? |
| Oct 22, 2015 PForm 4 → | Oct 26, 7:03 pm EDT | Alexander J DennerDirector | 310,000 | $277.47 | $86,015,000 | 310,000 | — | plan? |
| Oct 5, 2015 SForm 4 → | Oct 6, 4:40 pm EDT | Adriana KaraboutisEVP, Tech. and Bus. Solutions | 269 | $291.43 | $78,395 | 8,094 | −3.22% | plan? |
| Oct 2, 2015 SForm 4 → | Oct 5, 4:10 pm EDT | Adriana KaraboutisEVP, Tech. and Bus. Solutions | 417 | $283.38 | $118,169 | 8,363 | −4.75% | plan? |
| Oct 1, 2015 FMForm 4 → | Oct 5, 4:10 pm EDT | Adriana KaraboutisEVP, Tech. and Bus. Solutions | 3,605 | $287.30 | $478,642 | 8,780 | — | plan? |
| Jul 27, 2015 PForm 4 → | Jul 27, 5:03 pm EDT | Stelios PapadopoulosDirector | 10,000 | $304.88 | $3,048,775 | 5,000 | — | plan? |
| Jun 22, 2015 SForm 4 → | Jun 23, 4:14 pm EDT | Brian S PosnerDirector | 470 | $415.00 | $195,050 | 5,275 | −8.18% | plan? |
| Jun 19, 2015 SForm 4 → | Jun 22, 4:15 pm EDT | Douglas E WilliamsEVP Research & Development | 3,841 | $410.00 | $1,574,810 | 11,817 | −24.5% | plan? |
| Jun 15, 2015 SForm 4 → | Jun 16, 6:54 pm EDT | Brian S PosnerDirector | 400 | $386.64 | $154,656 | 5,745 | −6.51% | plan? |
| Jun 10, 2015 AForm 4 → | Jun 11, 4:34 pm EDT | Stephen A SherwinDirector | 695 | — | — | 4,845 | — | plan? |
| Jun 10, 2015 AForm 4 → | Jun 11, 4:33 pm EDT | Stelios PapadopoulosDirector | 1,040 | — | — | 16,580 | — | plan? |
| Jun 10, 2015 AForm 4 → | Jun 11, 4:32 pm EDT | Brian S PosnerDirector | 695 | — | — | 6,145 | — | plan? |
| Jun 10, 2015 AForm 4 → | Jun 11, 4:31 pm EDT | Lynn SchenkDirector | 695 | — | — | 4,890 | — | plan? |
| Jun 10, 2015 AForm 4 → | Jun 11, 4:30 pm EDT | Richard MulliganDirector | 695 | — | — | 7,890 | — | plan? |
| Jun 10, 2015 AForm 4 → | Jun 11, 4:28 pm EDT | Robert W PangiaDirector | 695 | — | — | 15,568 | — | plan? |
| Jun 10, 2015 AForm 4 → | Jun 11, 4:27 pm EDT | Caroline DorsaDirector | 695 | — | — | 16,033 | — | plan? |
| Jun 10, 2015 AForm 4 → | Jun 11, 4:24 pm EDT | Alexander J DennerDirector | 695 | — | — | 7,890 | — | plan? |
| Jun 10, 2015 AForm 4 → | Jun 11, 4:22 pm EDT | Nancy LeamingDirector | 695 | — | — | 7,924 | — | plan? |
| Jun 10, 2015 AForm 4 → | Jun 11, 4:21 pm EDT | Eric K RowinskyDirector | 695 | — | — | 12,005 | — | plan? |
| Jun 2, 2015 FMForm 4 → | Jun 4, 5:49 pm EDT | Adam KoppelSVP, Chief Strategy Officer | 3,236 | $387.62 | $330,252 | 1,662 | — | plan? |
| Jun 1, 2015 SForm 4 → | Jun 2, 4:10 pm EDT | George A ScangosChief Executive Officer, Director | 1,362 | $398.87 | $543,261 | 41,090 | −3.21% | plan? |
| May 1, 2015 FMForm 4 → | May 5, 4:36 pm EDT | Gregory F CovinoVP, Chief Accounting Officer | 460 | $386.22 | $177,661 | 1,761 | — | plan? |
| May 1, 2015 SForm 4 → | May 5, 4:34 pm EDT | George A ScangosChief Executive Officer, Director | 1,362 | $377.52 | $514,182 | 42,452 | −3.11% | plan? |
| Apr 2, 2015 FMForm 4 → | Apr 3, 4:24 pm EDT | Spyridon Artavanis-TsakonasSVP, Chief Scientific Officer | 1,435 | $412.44 | $189,722 | 1,674 | — | plan? |
| Apr 1, 2015 SForm 4 → | Apr 2, 4:29 pm EDT | George A ScangosChief Executive Officer, Director | 1,362 | $423.20 | $576,398 | 43,814 | −3.01% | plan? |
| Mar 27, 2015 SForm 4 → | Mar 30, 4:13 pm EDT | Alfred SandrockGrp SVP, Chief Medical Officer | 430 | $430.12 | $184,952 | 8,574 | −4.78% | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 22, 2016 AForm 4 → | Feb 24, 6:07 pm EST | Adam KoppelEVP, Strategy and Bus. Dev. | 7,270 | — | — | 7,270 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 6:03 pm EST | George A ScangosChief Executive Officer, Director | 19,683 | — | — | 10,502 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 6:01 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 4,692 | — | — | 2,448 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 6:00 pm EST | Kenneth DiPietroEVP Human Resources | 4,734 | — | — | 2,494 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 5:59 pm EST | Gregory F CovinoVP, Chief Accounting Officer | 571 | — | — | 258 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 5:57 pm EST | Alfred SandrockEVP CMO Neuro & Neurodegenerat | 5,458 | — | — | 10,006 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 5:56 pm EST | Steven H HoltzmanEVP Corporate Development | 4,588 | — | — | 2,448 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 5:55 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 4,810 | — | — | 2,674 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 5:54 pm EST | Spyridon Artavanis-TsakonasSVP, Chief Scientific Officer | 1,512 | — | — | 804 | — | |
| Feb 12, 2016 JMForm 4 → | Feb 17, 5:53 pm EST | Paul J ClancyExecutive VP and CFO | 5,253 | — | — | 2,448 | — | |
| Feb 9, 2016 MForm 4 → | Feb 10, 4:19 pm EST | George A ScangosChief Executive Officer, Director | 11,274 | — | — | 0 | — | |
| Feb 8, 2016 MForm 4 → | Feb 10, 4:17 pm EST | Alfred SandrockEVP CMO Neuro & Neurodegenerat | 1,278 | — | — | 0 | — | |
| Feb 8, 2016 MForm 4 → | Feb 9, 4:58 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 2,498 | — | — | 0 | — | |
| Feb 8, 2016 MForm 4 → | Feb 9, 4:53 pm EST | Paul J ClancyExecutive VP and CFO | 3,194 | — | — | 0 | — | |
| Feb 8, 2016 MForm 4 → | Feb 9, 4:51 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 4,026 | — | — | 0 | — | |
| Feb 8, 2016 MForm 4 → | Feb 9, 4:48 pm EST | Steven H HoltzmanEVP Corporate Development | 2,709 | — | — | 0 | — | |
| Feb 1, 2016 MForm 4/A → | Feb 9, 5:08 pm EST | Kenneth DiPietroEVP Human Resources | 2,466 | — | — | 1 | — | |
| Feb 1, 2016 MForm 4 → | Feb 2, 4:05 pm EST | Kenneth DiPietroEVP Human Resources | 2,466 | — | — | 1 | — | amended |
| Oct 1, 2015 JMForm 4 → | Oct 5, 4:10 pm EDT | Adriana KaraboutisEVP, Tech. and Bus. Solutions | 4,262 | — | — | 8,528 | — | |
| Jun 2, 2015 JMForm 4 → | Jun 4, 5:49 pm EDT | Adam KoppelSVP, Chief Strategy Officer | 3,612 | — | — | 7,228 | — | |
| May 1, 2015 MForm 4 → | May 5, 4:36 pm EDT | Gregory F CovinoVP, Chief Accounting Officer | 347 | — | — | 348 | — | |
| Apr 2, 2015 MForm 4 → | Apr 3, 4:24 pm EDT | Spyridon Artavanis-TsakonasSVP, Chief Scientific Officer | 975 | — | — | 975 | — | |
| Mar 25, 2015 MForm 4 → | Mar 26, 4:31 pm EDT | John CoxEVP Pharmaceutical Oper & Tech | 5,066 | — | — | 2,892 | — | |
| Mar 20, 2015 MForm 4 → | Mar 23, 4:33 pm EDT | Eric K RowinskyDirector | 11,667 | — | — | 0 | — | |
| Mar 19, 2015 MForm 4 → | Mar 20, 5:03 pm EDT | Eric K RowinskyDirector | 2,333 | — | — | 11,667 | — | |
| Mar 17, 2015 MForm 4 → | Mar 18, 5:03 pm EDT | Eric K RowinskyDirector | 4,667 | — | — | 14,000 | — | |
| Mar 10, 2015 MForm 4 → | Mar 11, 4:17 pm EDT | Stephen A SherwinDirector | 6,000 | — | — | 10,675 | — | |
| Mar 10, 2015 MForm 4 → | Mar 11, 4:13 pm EDT | Robert W PangiaDirector | 3,625 | — | — | 5,450 | — | |
| Mar 9, 2015 MForm 4 → | Mar 11, 4:15 pm EDT | Eric K RowinskyDirector | 4,666 | — | — | 18,667 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:20 pm EST | George A ScangosChief Executive Officer, Director | 26,550 | — | — | 26,550 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:19 pm EST | Stuart A KingsleyEVP, Global Comm. Operations | 6,220 | — | — | 6,220 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:18 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 7,260 | — | — | 7,260 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:16 pm EST | Alfred SandrockGrp SVP, Chief Medical Officer | 3,110 | — | — | 3,110 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:15 pm EST | Spyridon Artavanis-TsakonasSVP, Chief Scientific Officer | 1,300 | — | — | 1,300 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:14 pm EST | Paul J ClancyExecutive VP and CFO | 5,190 | — | — | 5,190 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:13 pm EST | Douglas E WilliamsEVP Research & Development | 8,300 | — | — | 8,300 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:11 pm EST | Adriana KaraboutisEVP, Tech. and Bus. Solutions | 4,460 | — | — | 4,460 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:10 pm EST | Steven H HoltzmanEVP Corporate Development | 5,190 | — | — | 5,190 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:08 pm EST | Adam KoppelSVP, Chief Strategy Officer | 2,700 | — | — | 2,700 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:07 pm EST | Kenneth DiPietroEVP Human Resources | 5,700 | — | — | 5,700 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:06 pm EST | Gregory F CovinoVP, Chief Accounting Officer | 600 | — | — | 600 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 6:02 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 5,700 | — | — | 5,700 | — | |
| Feb 12, 2015 MForm 4/A → | Mar 3, 2016, 4:27 pm EST | George A ScangosChief Executive Officer, Director | 9,189 | — | — | 18,380 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 9:32 pm EST | George A ScangosChief Executive Officer, Director | 19,692 | — | — | 20,996 | — | amended |
| Feb 12, 2015 JMForm 4 → | Feb 17, 9:16 pm EST | Gregory F CovinoVP, Chief Accounting Officer | 571 | — | — | 514 | — | amended |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:54 pm EST | Steven H HoltzmanEVP Corporate Development | 4,588 | — | — | 4,894 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:50 pm EST | Spyridon Artavanis-TsakonasSVP, Chief Scientific Officer | 1,512 | — | — | 1,602 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:47 pm EST | Alfred SandrockGrp SVP, Chief Medical Officer | 2,124 | — | — | 2,668 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:44 pm EST | Paul J ClancyExecutive VP and CFO | 5,253 | — | — | 4,894 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:40 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 4,692 | — | — | 4,894 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:37 pm EST | Douglas E WilliamsEVP Research & Development | 6,241 | — | — | 5,342 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:34 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 4,810 | — | — | 5,342 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:30 pm EST | Kenneth DiPietroEVP Human Resources | 4,734 | — | — | 4,982 | — | |
| Feb 12, 2015 JMForm 4 → | Feb 17, 8:26 pm EST | Stuart A KingsleyEVP, Global Comm. Operations | 4,468 | — | — | 4,448 | — | |
| Feb 9, 2015 MForm 4 → | Feb 11, 4:25 pm EST | George A ScangosChief Executive Officer, Director | 30,103 | — | — | 0 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:14 pm EST | Douglas E WilliamsEVP Research & Development | 3,468 | — | — | 3,471 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:12 pm EST | Susan H AlexanderEVP, Chief Legal Officer | 6,407 | — | — | 0 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:11 pm EST | Alfred SandrockGrp SVP, Chief Medical Officer | 3,101 | — | — | 0 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:10 pm EST | Steven H HoltzmanEVP Corporate Development | 2,705 | — | — | 2,709 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:08 pm EST | Stuart A KingsleyEVP, Global Comm. Operations | 4,460 | — | — | 0 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:07 pm EST | John CoxEVP Pharmaceutical Oper & Tech | 8,714 | — | — | 0 | — | |
| Feb 8, 2015 MForm 4 → | Feb 10, 5:06 pm EST | Paul J ClancyExecutive VP and CFO | 7,882 | — | — | 0 | — | |
| Feb 1, 2015 MForm 4 → | Feb 2, 7:46 pm EST | Kenneth DiPietroEVP Human Resources | 2,463 | — | — | 2,467 | — | |
| Feb 1, 2015 MForm 4 → | Feb 2, 7:43 pm EST | Douglas E WilliamsEVP Research & Development | 5,157 | — | — | 0 | — | |
| Feb 1, 2015 MForm 4 → | Feb 2, 7:40 pm EST | Steven H HoltzmanEVP Corporate Development | 5,157 | — | — | 0 | — |
Filed by this entity as an insider elsewhere — common stock
| Trade | Reported (ET) | Company | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2017 JForm 4 → | Feb 1, 5:21 pm EST | Bioverativ Inc.BIVV | 107,975,968 | — | — | 0 | — | plan? |
Filed by this entity as an insider elsewhere — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.